Online Only Articles

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal
Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal
Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University
Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal
Vol. 100 No. 1 (2015): January, 2015 https://doi.org/10.3324/haematol.2014.111245